IP Library › Granted Patent US 11,903,697
Granted Patent B2
US 11,903,697 · App. 14/975,437 · Granted Feb 20, 2024

System and method for mode switching

Inventors: Naresh C. Bhavaraju (San Diego, CA); Michael A. Bloom (Carlsbad, CA); Leif N. Bowman (San Diego, CA); Alexandra Lynn Carlton (San Marcos, CA); Katherine Yerre Koehler (Solana Beach, CA); Hari Hampapuram (Carlsbad, CA); Lauren Hruby Jepson (San Diego, CA); Jonathan Hughes (Carlsbad, CA); Apurv Ullas Karnath (San Diego, CA); Anna Leigh Davis (Cardiff, CA); Peter C. Simpson (Cardiff, CA); Stephen J. Vanslyke (Carlsbad, CA)
Assignee: DEXCOM, INC.
A61B5/14532A61B5/0002A61B5/1455A61B5/1486A61B5/1495A61B5/14503A61B5/14546A61B5/7221A61B5/7275A61B5/7282A61B5/742A61B5/746A61B5/7435A61B5/7475A61M5/1723G16H40/40G16H40/63A61B5/0004A61B5/6898A61B5/72A61B2560/0223A61B2560/0487A61M2230/005A61M2230/201Y02A90/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,903,697
App. No.
14/975,437
Granted
Feb 20, 2024
Kind
B2
Abstract

Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user's interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like.

Claims (30)

1. A computer-implemented method comprising:

receiving measurement data indicative of a glucose concentration of a user measured by a glucose sensor of an artificial pancreas system, the artificial pancreas system including the glucose sensor and an insulin delivery pump;

controlling the artificial pancreas system to operate in a therapeutic mode in which a numerical value of the glucose concentration of the user is displayed via a user interface and the insulin delivery pump is controlled to automatically administer insulin to the user based on the glucose concentration of the user measured by the glucose sensor of the artificial pancreas system, wherein the artificial pancreas system is configured to operate in a closed loop while in the therapeutic mode;

transitioning the artificial pancreas system directly from the therapeutic mode to an adjunctive mode based on a comparison of real time usability data against one or more transition criteria, wherein the real time usability data indicates a reliability or accuracy of the measurement data received from the glucose sensor, and wherein the transitioning from the therapeutic mode to the adjunctive mode occurs when the real time usability data indicates that the reliability or accuracy of the measurement data received from the glucose sensor is below a threshold; and

receiving subsequent measurement data indicative of a subsequent glucose concentration of the user measured by the glucose sensor of the artificial pancreas system; and

controlling the artificial pancreas system to operate in the adjunctive mode in which a visual indication of a zone, range, or trend associated with the subsequent glucose concentration is displayed via the user interface, wherein the subsequent measurement data received from the glucose sensor is not used to control the insulin delivery pump while the artificial pancreas system is operating in the adjunctive mode.

2. The method of claim 1 , wherein the real time usability data includes diagnostic data.

3. The method of claim 1 , wherein the real time usability data includes parameters entered by a user in a setup mode.

4. The method of claim 1 , wherein the real time usability data corresponds to a level of confidence in the measurement data.

5. The method of claim 1 , wherein the real time usability data includes data from diagnostic tests.

6. The method of claim 1 , further comprising transitioning the artificial pancreas system directly from the adjunctive mode back into the therapeutic mode based on subsequent real time usability data.

7. The method of claim 1 , further comprising transitioning the artificial pancreas system directly from the adjunctive mode to an additional mode based on subsequent real time usability data.

8. The method of claim 7 , wherein the additional mode comprises controlling the insulin delivery pump to automatically administer insulin to the user based on the glucose concentration of the user measured by the glucose sensor of the artificial pancreas system when the glucose concentration of the user is above a low threshold.

9. The method of claim 8 , wherein the insulin delivery pump is controlled to turn off when the glucose concentration of the user is below the low threshold.

10. The method of claim 7 , wherein the additional mode comprises controlling the insulin delivery pump to automatically administer insulin to the user based on the glucose concentration of the user measured by the glucose sensor of the artificial pancreas system, and causing an alarm when the glucose concentration of the user is below a low threshold.

11. The method of claim 10 , wherein the additional mode further comprises controlling the insulin delivery pump to administer insulin to the user when the glucose concentration of the user is above a high threshold.

12. The method of claim 7 , wherein the additional mode comprises controlling the insulin delivery pump to automatically administer insulin to the user based on the glucose concentration of the user measured by the glucose sensor of the artificial pancreas system, and enabling manual bolusing of insulin for meals.

13. The method of claim 1 , wherein the insulin delivery pump is worn by the user.

14. The method of claim 1 , wherein the controlling the artificial pancreas system to operate in the therapeutic mode further comprises:

modifying, based at least in part on the glucose concentration of the user, a basal dose of insulin to deliver to the user; and

controlling the insulin delivery pump to deliver the modified basal insulin dose to the user.

15. The method of claim 1 , wherein the controlling the artificial pancreas system to operate in the therapeutic mode further comprises:

modifying, based at least in part on the glucose concentration of the user, a bolus dose of insulin to deliver to the user; and

controlling the insulin delivery pump to deliver the modified bolus insulin dose to the user.

16. The method of claim 1 , further comprising providing a prompt for selection by the user after transitioning to the adjunctive mode, wherein the visual indication of the zone, range, or trend associated with the subsequent glucose concentration is not displayed via the user interface until the prompt is selected by the user.

17. The method of claim 1 , further comprising displaying, in the user interface, an additional visual indication of the therapeutic mode while operating in the therapeutic mode and of the adjunctive mode while operating in the adjunctive mode.

18. The method of claim 1 , wherein the transition criteria is based at least partially on a time or day of week.

19. The method of claim 1 , wherein the visual indication comprises the zone associated with the subsequent glucose concentration.

20. The method of claim 1 , wherein the visual indication comprises the range associated with the subsequent glucose concentration.

21. The method of claim 1 , wherein the visual indication comprises the trend associated with the subsequent glucose concentration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: DAVIS, ANNA LEIGH
To: DEXCOM, INC.
Reel/Frame 065506/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2016
From: GRUBSTEIN, KATHERINE YERRE
To: DEXCOM, INC.
Reel/Frame 037559/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2016
From: BHAVARAJU, NARESH C.; BLOOM, MICHAEL A.; CARLTON, ALEXANDRA LYNN; HAMPAPURAM, HARI; JEPSON, LAUREN HRUBY; HUGHES, JONATHAN; KAMATH, APURV ULLAS; RACK-GOMER, ANNA LEIGH; SIMPSON, PETER C.; VANSLYKE, STEPHEN J.; BOWMAN, LEIF N.
To: DEXCOM, INC.
Reel/Frame 037500/0756 →
Continuity (3)
Continuation 14862079 · Sep 22, 2015
Provisional Application 62053733 · Sep 22, 2014
Related Publication 20160113558A1 · Apr 28, 2016
Cited By (2)
US 12,357,201 US 12,648,716